Want to see APYX full AI Analyst Report?
APYX Stock Chart & Stats
$3.05
-$0.03(-0.77%)
At close: 4:00 PM EDT
$3.05
-$0.03(-0.77%)
Day’s Range― - ―
52-Week Range$2.32 - $5.08
Previous Close$3.83
Volume71.39K
Average Volume (3M)137.27K
Market Cap
$101.94M
Enterprise Value$209.33M
Total Cash (Recent Filing)$27.62M
Total Debt (Recent Filing)$39.63M
Price to Earnings (P/E)―
Beta1.76
Next Earnings
Nov 05, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding42,124,023
10 Day Avg. Volume104,474
30 Day Avg. Volume137,268
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)10.15
Price to Sales (P/S)2.79
P/FCF Ratio-16.19
Enterprise Value/Market Cap2.05
Enterprise Value/Revenue3.58
Enterprise Value/Gross Profit10.56
Enterprise Value/Ebitda-130.42
Forecast
1Y Price Target
$6.33Price Target Upside107.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.27
Revenue Forecast (FY)$59.45M
Bulls Say, Bears Say
Bulls Say
Surgical Aesthetics GrowthStrong Surgical Aesthetics growth indicates expanding demand for Apyx’s core platform, supported by AYON sales, international generator placements and higher handpiece volume. Continued adoption can enlarge the installed base and create recurring consumable revenue over the next several quarters.
Product And Regulatory MomentumExpanded FDA clearance broadens AYON’s clinical use and strengthens its commercial proposition for physicians. Management expects more than 95% of new AYON purchasers to include Power Lipo, which could support platform adoption, procedure volume and future accessory demand.
Clinical DifferentiationHuman clinical evidence showing improved elastin measures, reduced inflammation and high patient satisfaction supports Renuvion’s positioning in aesthetic procedures. Published data may help physician adoption and reinforce competitive differentiation beyond product features alone.
Bears Say
Persistent Cash BurnNegative operating and free cash flow show that Apyx is not yet funding operations internally. Continued cash consumption can constrain investment in sales, product launches and clinical programs, while increasing reliance on its available liquidity and external funding capacity.
Elevated LeverageDebt materially exceeds the company’s equity base, leaving a limited cushion against operating setbacks. This leverage can reduce financial flexibility, increase pressure to preserve cash and make it harder to fund growth initiatives while the company remains unprofitable.
OEM Decline And Launch CostsThe declining OEM business creates a structural revenue headwind as growth depends more heavily on Surgical Aesthetics. At the same time, elevated initial Power Lipo production costs could pressure margins until manufacturing scales and unit economics improve.
Apyx Medical News
APYX FAQ
What was Apyx Medical Corporation’s price range in the past 12 months?
Apyx Medical Corporation lowest stock price was $2.32 and its highest was $5.08 in the past 12 months.
What is Apyx Medical Corporation’s market cap?
Apyx Medical Corporation’s market cap is $101.94M.
When is Apyx Medical Corporation’s upcoming earnings report date?
Apyx Medical Corporation’s upcoming earnings report date is Nov 05, 2026 which is in 15 days.
How were Apyx Medical Corporation’s earnings last quarter?
Apyx Medical Corporation released its earnings results on Aug 06, 2026. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.082 by $0.012.
Is Apyx Medical Corporation overvalued?
According to Wall Street analysts Apyx Medical Corporation’s price is currently Undervalued.
Does Apyx Medical Corporation pay dividends?
Apyx Medical Corporation does not currently pay dividends.
What is Apyx Medical Corporation’s EPS estimate?
Apyx Medical Corporation’s EPS estimate is -0.09.
How many shares outstanding does Apyx Medical Corporation have?
Apyx Medical Corporation has 42,124,023 shares outstanding.
What happened to Apyx Medical Corporation’s price movement after its last earnings report?
Apyx Medical Corporation reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.082. Following the earnings report the stock price went down -2.644%.
Which hedge fund is a major shareholder of Apyx Medical Corporation?
Currently, no hedge funds are holding shares in APYX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Apyx Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.33 (107.65% Upside)
$6.33 (107.65% Upside)
Blogger Sentiment
Bearish
APYX Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 662.8K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.04%
12-Months-Change
Fundamentals
Return on Equity
-78.70%
Trailing 12-Months
Asset Growth
4.96%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Apyx Medical Corporation
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures; and a portfolio of single-use handpieces and accessories for open and laparoscopic procedures. The company’s helium plasma technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
APYX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented solid commercial and clinical momentum: double-digit top-line growth (22% total, 28% surgical aesthetics), improved gross profit/margin and narrower operating and adjusted EBITDA losses, supported by FDA clearance for power liposuction and favorable clinical data. Offsetting risks include continued OEM decline, increased operating cash use and near-term manufacturing/cost pressures for new Power Lipo units, plus tariff-related cost uncertainty. On balance, the positive revenue and margin trends, clinical validation, product approvals and reaffirmed guidance outweigh the challenges.View all APYX earnings summariesAPYX Stock 12 Month Forecast
Average Price Target
$6.33
▲(107.65% Upside)
Technical Analysis
Ownership Overview
6.77% Insiders
8.83% Mutual Funds
3.34% Other Institutional Investors
77.11% Public Companies and
Individual Investors